medical hospital

When general population discuss contemporary medicine, precision plays one of the most crucial roles and people’s lives are literally dependent on it. Likewise, any researches pertaining to medicine are necessary to meet the top standards. The problem nowadays is that any recommendations of researches can be published online and used as a reference without being adequately verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and decided to generate an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality measure. That allows both readers and authors to quality-check publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a full publications list with corre

Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib. Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation. The Oncotarget authors analyzed whether paradox breakers reduce pathway reactivation and so have enhanced potency compared with encorafenib in BRAF mutant CRC. However, dose-response curves for encorafenib and PLX8394 were similar and there were no significant differences in the degree of pathway reactivation. To their knowledge, these data represent the first comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC. Dr. Gary W. Middleton from The Institute of Immunolog

When general population refer to modern medicine, precision plays one of the most important roles and human lives are literally dependent on it. Hereby, any researches related to medicine are necessary to meet the highest standards. The issue nowadays is that any recommendations of researches can be posted online and used as a reference without being adequately checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and tried to generate an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That assists both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website has a complete publications list with corresponding scores a

 The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21. Paradoxically, the increased expression of p21 correlates with a reduced cell killing to the drug. HDAC inhibitors appear to activate p21 expression via ataxia telangiectasia mutated activity. The Oncotarget authors explored the potential synergistic interaction of the ATM inhibitor with romidepsin, given the potential complementary impact around p21. A synergistic cytotoxic effect was observed in all lymphoma cell lines examined when the HDACi was combined with KU60019. The increase in apoptosis correlates with decreased expression of p21 due to the ATM inhibitor. KU60019 decreased expression of the cyclin-dependent kinase inhibitor

When general population refer to modern medicine, precision plays one of the most crucial roles and people’s lives are directly dependent on it. Hence, any researches related to medicine are required to comply with the top standards. The issue nowadays is that any outcomes of researches can be published online and used as a reference without being thoroughly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and attempted to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to quality-check publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with correspo

When general population discuss modern medicine, precision plays one of the most important roles and human lives are literally dependent on it. Hereby, any researches pertaining to medicine are necessary to comply with the top standards. The challenge nowadays is that any results of researches can be shared online and used as a reference without being properly checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this problem and tried to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality indicator. That assists both readers and authors to quality-check publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with corresponding

  The cover for   issue 39   of   Oncotarget   features Figure 4, " Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves, " by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1. The cell surface overexpression of NRXN1 was confirmed using flow cytometry in SCLC cell lines. The combination of a primary anti-NRXN1 monoclonal antibody and a secondary ADC exhibited anti-tumor activity in SCLC cell lines. Moreover, the knockout of NRXN1 in SHP77 cells resulted in a loss of the anti-tumor activity of NRXN1-mediated ADC therapy. Thus, NRXN1 could be a novel target for ADC therapy for the treatment of SCLC that is worth further research. Dr. Daiya Takai from The University of Tokyo Hospital and Dr. Takuma Yotsumoto from The University of Tokyo Graduate School of Medicine s

When people speak of modern medicine, precision plays one of the most crucial roles and people’s lives are literally dependent on it. Likewise, any researches pertaining to medicine are necessary to meet the top standards. The problem nowadays is that any results of researches can be published online and used as a reference without being thoroughly checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality indicator. That helps both readers and authors to verify publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a full publications list with respective scores higher than 100 as

The cover for Issue 42 of Oncotarget features Figure 4, "Generation of parametric and texture maps from radiofrequency data," recently published in "Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer" by Dasgupta, et al. which reported that to investigate quantitative ultrasound based higher-order texture derivatives in predicting the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Three machine learning algorithms based on linear discriminant, k-nearest-neighbors, and support vector machine were used for developing radiomic models of response prediction. The most helpful features in separating the two response groups were QUS-Tex1-Tex2 features. The 5-year recurrence-free survival calculated for KNN predicted responders and non-responders using QUS-Tex1-Tex2 model was comparable to RFS for the actual response groups.

When general population discuss today’s medicine, precision plays one of the most crucial roles and human lives are directly dependent on it. Hereby, any researches pertaining to medicine are required to meet the highest standards. The problem today is that any recommendations of researches can be published online and used as a reference without being precisely checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and tried to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality indicator. That helps both readers and authors to verify publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with corresponding score

When public discuss contemporary medicine, precision plays one of the most important roles and human lives are directly dependent on it. Hereby, any researches pertaining to medicine are required to meet the top standards. The issue nowadays is that any recommendations of researches can be posted online and used as a reference without being thoroughly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and attempted to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That helps both readers and authors to verify publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a complete publications list with respective scores above 10